Harold H. Shlevin, PhD
President and chief executive officer
Dr. Shlevin is a bioscience industry executive with 25 years of senior management experience in the development and commercialization of pharmaceuticals, diagnostics and vaccines. Before joining Galectin Therapeutics, Dr. Shlevin led Georgia Institute of Technology’s Advanced Technology Development Center (ATDC) as principal and manager of bioscience commercialization efforts, where he served as a catalyst for new bioscience startup companies. His leadership roles have included president and chief executive officer of Solvay Pharmaceuticals, where he oversaw the successful launch of the first topical testosterone gel product in the US; co-founder of CIBA Vision Ophthalmics, a specialty ophthalmic drug company, where he headed efforts leading to the approval of the first non-steroidal agent for treatment of ocular inflammation and several other drug products; founder, president and chief executive officer of Tikvah Therapeutics, a company focused on clinical development of therapeutics for treatment of neurological diseases; and vice president and head of operations and commercial development for Altea Therapeutics Corporation, a clinical-stage drug delivery company with platform technology applicable to the transdermal delivery of biologics. Dr. Shlevin earned his B.A. from Boston University and M.S. and Ph.D. in physiology from the University of Rochester Medical School. He completed post-doctoral training in pharmacology at Mayo Clinic where he subsequently served as assistant professor of pharmacology and physiology. He is a member of scientific and business societies including the Institute of Electrical and Electronics Engineers, Licensing Executives Society, American Physiological Society, American Society of Pharmacology and Experimental Therapeutics, and is an inventor on several issued and pending patents.
Pol F. Boudes M.D.
Chief Medical Officer
Dr. Boudes has more than 25 years of experience in clinical drug development in immunology, endocrine, metabolic, orphan, and liver-related diseases, and he has contributed to the approval of multiple drugs, both in the US and globally, across a variety of therapeutic indications. Before joining Galectin Therapeutics, Dr. Boudes was the chief medical officer at CymaBay Therapeutics -- where he worked on the company’s proprietary NASH compound and was instrumental in inventing and launching programs in rare liver diseases. Prior to CymaBay, Dr. Boudes was CMO at Amicus Therapeutics, a company focusing on rare lysosomal storage disorders. His prior positions include clinical development at Bayer HealthCare Pharmaceuticals, Wyeth Research, Hoffman-La Roche, and Pasteur Merieux.
A dual citizen of the U.S. and France, Dr. Boudes earned his MD at the University of Marseilles, France. He completed his internship and residency in Marseilles and Paris, was an assistant professor of medicine at the University of Paris, and also participated in multiple clinical research programs as an investigator. He is certified by the Educational Commission for Foreign Medical Graduates (US) and board-specialized in endocrinology and metabolic diseases, internal medicine, as well as in geriatric diseases (Paris).
Dr. Boudes holds several records of invention and has contributed to multiple peer-reviewed publications, notably on improving the clinical development process, and has served on the editorial review board for La Revue Prescrire -- a leading European Drug Therapeutic Bulletin -- as well as several scientific advisory boards for drug development. He is a member of several professional organizations, including the American Association for the Study of Liver Disease, the European Association for the Study of Liver (Geneva, Switzerland), the American Diabetes Association, the Royal Society of Medicine (London, U.K.), and the American Medical Association.
Jack W. Callicutt, CPA
Chief financial officer
Mr. Callicutt has over 24 years of public and private company experience including more than a decade of audit, tax and SEC registrant experience with a major accounting firm. He was most recently chief financial officer for REACH Health, Inc., a telemedicine firm, where he completed a $4 million private placement. Previous positions include chief financial officer of Vystar Corporation, a public medical device company whose latex products are devoid of antigenic proteins, where he led all areas of financial reporting, accounting, treasury, risk management and administration and secured over $4.5 million in financing. Previous experiences also include chief financial officer roles at private companies including IVOX and Tikvah Therapeutics, and at Coratus Genetics, a publicly-traded biopharmaceutical company. Mr. Callicutt is a certified public accountant and graduated cum laude with a B.B.A. degree in accounting and computer science from Delta State University.
Vice president, commercial development, regulatory affairs and quality assurance
Mr. Horton is an experienced industry professional with 20 years of management and leadership experience in global regulatory affairs matters including drugs, biologics and vaccines. He has broad range of regulatory affairs and quality leadership experience that is directly relevant to Galectin Therapeutics’ development programs, with expertise spanning preclinical development through new drug approvals in diverse therapeutic areas, including gastroenterology. He was most recently was director of regulatory affairs at Chelsea Therapeutics, where he successfully led the organization through its first NDA filing and favorable FDA Advisory Committee Meeting. In past leadership roles at Solvay Pharmaceuticals and Abbott Laboratories, he led approval efforts for key products including Androgel® Stickpack, Creon® Capsules and Luvox® CR Capsules. He has also provided chemistry, manufacturing and controls (CMC) regulatory leadership and support of INDs and NDAs, including Estrogel® and Androgel® Pump. Mr. Horton was a member of the executive leadership team that successfully implemented solutions to significant regulatory issues encountered by Solvay in its interactions with the FDA. He earned his Bachelor’s degree in industrial/manufacturing and systems engineering from the Georgia Institute of Technology. He is a member of the Regulatory Affairs Professional Society (RAPS), Drug Information Association (DIA) and American Association of Pharmaceutical Scientists (AAPS).
Adam E. Allgood, Pharm.D., R.Ph.
Executive director of clinical development
Dr. Allgood is an experienced industry professional with more than 28 years of pharmaceutical industry experience in effectively designing, implementing, monitoring, and directing clinical programs in all four phases of clinical development, ranging from Phase 1 first-in-human trials to large global Phase 3 clinical trials and post marketing trials. His therapeutic expertise spans a variety of therapeutic areas including gastroenterology, and encompasses clinical trial leadership, key opinion leader interface, significant contract research organization management experience, clinical trial investigator training, and clinical advisory board responsibilities. In addition, Dr. Allgood has extensive clinical research and/or regulatory experience in immunology, rheumatology, neurology, and women’s health. Dr. Allgood most recently was associate director of global pharmaceutical regulatory affairs at UCB Inc., a multinational biopharmaceutical company. His prior positions include leadership roles at Abbott Laboratories and Solvay Pharmaceuticals in regulatory affairs, clinical development and medical affairs. Dr. Allgood earned his Doctor of Pharmacy (Pharm.D.) degree summa cum laude from Mercer University College of Pharmacy and Health Sciences in Atlanta and is a Registered Pharmacist (R.Ph.). He is a member of the American Pharmacists Association (APHA), the Georgia Pharmacy Association (GPHA), and the Association of the United States Army (AUSA).
Eliezer Zomer Ph.D.
Vice president, discovery research and product development
Dr. Zomer is the founder of Alicon Biological Control, where he served from 2000 to 2002. He was vice president of product development at SafeScience, Inc., from 1998 to 2000, and from 1987 to 1998 was vice president of research and development at Charm Sciences, Inc. Dr. Zomer received a B.Sc. degree in industrial microbiology from the University of Tel Aviv, a Ph.D. in biochemistry from the University of Massachusetts in 1978, and completed his post-doctoral study at the National Institutes of Health.